Risk of early relapse following the switch from injectables to oral agents for multiple sclerosis

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00064165%3A_____%2F16%3A10323282" target="_blank" >RIV/00064165:_____/16:10323282 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00216208:11110/16:10323282

Výsledek na webu

<a href="http://dx.doi.org/10.1111/ene.12929" target="_blank" >http://dx.doi.org/10.1111/ene.12929</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1111/ene.12929" target="_blank" >10.1111/ene.12929</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Risk of early relapse following the switch from injectables to oral agents for multiple sclerosis

Popis výsledku v původním jazyce

Background and PurposeEarly relapse outcomes in long-term stable patients switching from interferon /glatiramer acetate (IFN/GA) to oral therapy are unknown. ObjectiveThe objective of this study was to compare early relapse and progression in multiple sclerosis (MS) patients switching to oral therapy following a period of stable disease on IFN/GA, relative to a propensity-matched comparator of patients remaining on IFN/GA. MethodsThe MSBase cohort study is a global, longitudinal registry for MS. Time to first 6-month relapse in previously stable MS patients switching from platform injectables (switchers') to oral agents were compared with propensity-matched patients remaining on IFN/GA (stayers') using a Cox marginal model. ResultsThree-hundred and ninety-six switchers were successfully matched to 396 stayers on a 1:1 basis. There was no difference in the proportion of patients recording at least one relapse in the first 1-6 months by treatment arm (7.3% switchers, 6.6% stayers; P = 0.675). The mean annualized relapse rate (P = 0.493) and the rate of first 6-month relapse by treatment arm (hazard ratio 1.22, 95% confidence interval 0.70, 2.11) were also comparable. There was no difference in the rate of disability progression by treatment arm (hazard ratio 1.43, 95% confidence interval 0.63, 3.26). ConclusionThis is the first study to compare early relapse switch probability in the period immediately following switch to oral treatment in a population previously stable on injectable therapy. There was no evidence of disease reactivation within the first 6 months of switching to oral therapy.

Název v anglickém jazyce

Risk of early relapse following the switch from injectables to oral agents for multiple sclerosis

Popis výsledku anglicky

Background and PurposeEarly relapse outcomes in long-term stable patients switching from interferon /glatiramer acetate (IFN/GA) to oral therapy are unknown. ObjectiveThe objective of this study was to compare early relapse and progression in multiple sclerosis (MS) patients switching to oral therapy following a period of stable disease on IFN/GA, relative to a propensity-matched comparator of patients remaining on IFN/GA. MethodsThe MSBase cohort study is a global, longitudinal registry for MS. Time to first 6-month relapse in previously stable MS patients switching from platform injectables (switchers') to oral agents were compared with propensity-matched patients remaining on IFN/GA (stayers') using a Cox marginal model. ResultsThree-hundred and ninety-six switchers were successfully matched to 396 stayers on a 1:1 basis. There was no difference in the proportion of patients recording at least one relapse in the first 1-6 months by treatment arm (7.3% switchers, 6.6% stayers; P = 0.675). The mean annualized relapse rate (P = 0.493) and the rate of first 6-month relapse by treatment arm (hazard ratio 1.22, 95% confidence interval 0.70, 2.11) were also comparable. There was no difference in the rate of disability progression by treatment arm (hazard ratio 1.43, 95% confidence interval 0.63, 3.26). ConclusionThis is the first study to compare early relapse switch probability in the period immediately following switch to oral treatment in a population previously stable on injectable therapy. There was no evidence of disease reactivation within the first 6 months of switching to oral therapy.

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FH - Neurologie, neurochirurgie, neurovědy

OECD FORD obor

—

Projekt

—

Návaznosti

V - Vyzkumna aktivita podporovana z jinych verejnych zdroju

Rok uplatnění

2016

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

European Journal of Neurology

ISSN

1351-5101

e-ISSN

—

Svazek periodika

23

Číslo periodika v rámci svazku

4

Stát vydavatele periodika

GB - Spojené království Velké Británie a Severního Irska

Počet stran výsledku

8

Strana od-do

729-736

Kód UT WoS článku

000372972300014

EID výsledku v databázi Scopus

2-s2.0-84955062203